Published studies, by compound
166 studies across 23 compounds in the Eon catalogue, each resolved against PubMed and linked to its record. The index is limited by rule to animal models and cell-based (in vitro) work: human trials, case reports and literature overviews are excluded before anything is listed, and a published title is never reworded. Each compound's page shows the evidence table, the research models used, and how the list was built.
- ARA-2908 studies, 2018 to 2025
- BPC-1578 studies, 2020 to 2026
- BPC-157 / TB-5006 studies, 2024 to 2026
- CJC / IPA Blend3 studies, 2002 to 2024
- DSIP8 studies, 2002 to 2021
- Epithalon8 studies, 2007 to 2025
- GHK-Cu8 studies, 2016 to 2026
- Glow9 studies, 2020 to 2026
- IGF-1 LR35 studies, 1997 to 2008
- Ipamorelin8 studies, 1998 to 2024
- Kisspeptin8 studies, 2018 to 2026
- KLOW12 studies, 1991 to 2026
- KPV4 studies, 1984 to 2013
- Melanotan II8 studies, 2015 to 2023
- MOTS-c8 studies, 2025 to 2026
- NAD+3 studies, 2020 to 2021
- Selank8 studies, 2017 to 2022
- Semax8 studies, 2018 to 2025
- SS-318 studies, 2022 to 2026
- TB-5008 studies, 2021 to 2026
- TB-500 / KPV / BPC-1579 studies, 1991 to 2026
- TESA / IPA Blend3 studies, 2002 to 2024
- Thymosin Alpha-18 studies, 2015 to 2024
Compounds without an index
A compound appears here only when at least three published studies pass every rule. Compounds whose literature is mainly clinical, whose published name differs from the catalogue name, or whose catalogue copy deliberately avoids a pharmaceutical name have no index page. Their monographs and certificate pages are unaffected.
For research use only. Not for human or veterinary use. Preclinical and in-vitro studies only: animal models and cell-based work indexed in PubMed. Human trials, case reports and literature overviews are excluded by rule.